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THE EFFECT OF CERVICAL INTRAEPITHELIAL NEOPLASIA AND 
TREATMENT SURGERIES ON FECUNDABILITY 
ALEXANDRA KLANN 
ABSTRACT 
Introduction: Approximately 6 million couples in the United States experience infertility. 
Because few risk factors for infertility are known, identification of modifiable 
determinants is an important public health goal. 
 Cervical intraepithelial neoplasia, CIN, occurs when the surface cells of the 
cervical tissue begin to change, and is caused by infection with a high-risk type of human 
Papillomavirus (HPV). CIN may affect the cervix’s immunological function, resulting in 
changes in mucus production, reduced protection against infections, and alterations in 
sperm transport through the cervical canal. CIN can also progress to invasive cervical 
cancer. There are four main CIN treatment procedures that aim to remove pre-cancerous 
cells from the cervix; loop excisions, commonly known as electrosurgical excision 
procedure (LEEP) or large loop excision of the transformative zone (LLETZ); 
cryosurgery; conization; and laser ablation. Because the goal of these procedures is to 
remove abnormal cells, healthy cervical cells may inadvertently be removed as well, 
leading to further changes in cervical mucus production, sperm motility, and reduced 
protection against infection. Because of the changes to the cervical tissue and its function, 
CIN and its surgical treatments may affect fecundability. 
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Methods: We analyzed data from Pregnancy Study Online (PRESTO), a preconception 
cohort of 5,594 North American pregnancy planners enrolled and followed between 2013 
and 2018. At baseline, participants reported whether they had abnormal Pap tests and 
their age at their first abnormal Pap test, as well as cervical procedures and their age at 
the procedure. We estimated fecundability ratios (FR) and 95% confidence intervals (CI) 
using proportional probabilities models adjusted for sociodemographics, smoking, 
number of sexual partners, history of sexually transmitted infections/ pelvic inflammatory 
disease, and HPV vaccination. 
 
Results: A history of abnormal Pap test, which we used as a proxy for cervical dysplasia, 
was positively associated with current and past smoking, gravidity, parity, irregular 
menses, number of sexual partners, history of chlamydia, genital warts and herpes, as 
well as a history of pelvic inflammatory disease. Of the women with an abnormal Pap 
test, the average age at first abnormal Pap test was 23.0 (std=4.5) years and the average 
number of abnormal Pap tests was 2.1 (std=1.7). 
We found little association overall between a history of abnormal Pap test and 
fecundability (FR=1.03, 95% CI: 0.96, 1.11). The results did not differ when the data 
were examined by number of abnormal Pap tests, or type of procedure. There was also 
little association between time since the diagnosis or procedure and pregnancy attempt 
and fecundability. There was however a slight decrease in fecundability within the first 2 
years of diagnosis/ procedure, with FRs that tended to increase with increasing time since 
diagnosis/procedure. 
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Discussion: We found little association overall between a history of abnormal Pap test or 
cervical dysplasia, including excisional surgeries, and fecundability. These results are 
consistent with most other studies demonstrating no clear adverse effects of CIN and 
treatments. Recency of diagnosis or procedure did not appreciably affect these findings. 
Although we found a very slight decrease in fecundability within the first two years since 
diagnosis or procedure, fecundability became similar to that of undiagnosed/untreated 
women after 2 years, and then increased slightly. 
 
Conclusion: We found little association between a history of abnormal Pap and CIN 
treatments and fecundability. A major limitation of our study is that the data were self-
reported, which may have resulted in non-differential exposure misclassification. 
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INTRODUCTION 
Infertility 
Approximately 6 million couples in the United States experience infertility, 
defined as the inability to conceive within 12 months of regular unprotected intercourse.1 
Known and suspected risk factors for infertility include advanced female age,2 3 genetic 
defects4, cigarette smoking,5 obesity,4 gynecological diseases such as endometriosis6 and 
uterine leiomyomata,7 and selected environmental agents.4 Use of assisted reproductive 
technologies (ART), such as in vitro fertilization (IVF), has increased dramatically in 
recent years,8 with U.S. health care costs for infertility treatment exceeding $5.5 billion.4 
Thus, infertility and its treatments are associated with financial and psychological 
hardship for affected couples. Finally, use of infertility treatments has been associated 
with adverse pregnancy and birth outcomes.9 10 11 12 Therefore, identification of 
modifiable determinants of infertility is an important public health goal. 
The extent to which cervical dysplasia and its associated treatments are associated 
with fertility is unclear. The present thesis will examine prospectively self-reported 
abnormal Papanicolaou (Pap) tests (as a proxy for cervical dysplasia), treatments for 
cervical dysplasia, and fecundability – the average per-cycle probability of conception 
among non-contracepting couples engaged in regular intercourse – in a preconception 
cohort of North American pregnancy planners.  
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Cervical dysplasia 
The cervix, the region of the female reproductive system located between the 
vagina and the uterus, is made up of the ectocervix and the endocervix. The ectocervix is 
the portion that extends into the vagina. The endocervix consists of the opening of the 
cervix into the uterine cavity.13 The cervix performs many functions, which include 
protecting the genital tract and fetus from infections, facilitating sperm transport into the 
fallopian tubes for fertilization, and maintaining pregnancy in the uterus until labor.13 
Cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia, occurs 
when the surface cells of the cervical tissue begin to change. Almost all CIN is caused by 
infection with a high-risk type of human papillomavirus (HPV).14 The changes that occur 
in the cervical cells because of CIN can lead to changes in the cervix immunological 
functions. This may affect changes in mucus production, disrupt protection against 
infections, alter sperm transport through the cervical canal, and can lead to cervical 
cancer.13 However, since the initiation of cervical cancer screening, or papanicolaou 
(Pap) tests, cervical cancer incidence in the United States has decreased by more than 
50%.15 If the Pap test result is abnormal, the colposcopy is a test for evaluating and 
determining the location of CIN.16 A colposcopy is a procedure that is performed using a 
colposcope, a microscope with various magnifying lenses, that examines the cervix, 
vagina, and vulva.17 A biopsy and pathology will then follow the colposcopy in order to 
diagnose the patient with CIN. There are two main types of CIN, low-grade CIN (CIN1) 
and high-grade CIN (CIN2 and CIN3). CIN1 is considered a marker of an active HPV 
infection. This type of CIN usually regresses without treatment, and patients will usually 
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undergo a repeat Pap test with or without an HPV test within 6-12 months of diagnosis to 
monitor the abnormal cervical cells.18 Unvaccinated women who are sexually active 
under the age of 30 have a higher rate of HPV compared with women over the age of 
30.19 This means that younger women of reproductive age are more susceptible to HPV 
infection and CIN1 compared with older women, but low grade CIN in young women has 
a 50% regression rate and only 10% progression rate.20 
CIN2 and CIN3 are considered markers of pre-cancerous cells, and patients will 
undergo a colposcopy, in addition to a cervical biopsy. In order to treat CIN2 and CIN3, 
local ablative or excisional methods are required to remove the affected cervical cells 
depending on the extent of the disease.18 Ablative procedures remove tissue with high 
heat, such as lasers or electrical current. The most common procedures are loop 
excisions, commonly known as electrosurgical excision procedure (LEEP) or large loop 
excision of the transformative zone (LLETZ), cryosurgery, conization, and laser ablation. 
Of these procedures, LEEP has been used for almost 25 years in the United States and is 
the most common treatment for CIN.21 
 
CIN surgical procedures 
The goal of all surgical procedures for cervical dysplasia is to remove the 
abnormal cells to prevent or remove cervical cancer. However, healthy endocervical 
tissue may inadvertently be removed. Depending on the provider, and the extent of 
dysplasia, the chosen procedure will remove or destroy varying amounts of cervical 
tissue. The two most common and preferred excisional methods for treatment of CIN are 
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laser conization and LEEP.22 The difference between the two surgeries is the volume of 
tissue removed. One study found that the volume of tissue removed during conization 
was appreciable greater than LEEP. 22 The conization procedure removed a median 
volume of 1.84cm3 (95% CI 1.98–2.54 cm3) compared with the LEEP procedures median 
volume of 0.78 cm3 (95% CI 0.91–1.02 cm3). Regeneration of the cervical tissue is 
possible, but it is dependent on the amount of tissue initially removed. As more of the 
tissue is removed, the lower the likelihood of regeneration.23 
Because these procedures remove different amounts of cervical tissue, they may 
have varying adverse effects on the functions of the cervix.22 For example, a meta-
analysis study by Kyrgious et al. suggested higher rates of adverse birth outcomes among 
women who had excisional treatments compared to laser ablation.21 These procedures can 
lead to further reduction in cervical mucus production, changes in sperm motility and 
reduced protection against infection.24 In more extreme cases, removal of cervical tissue 
may cause cervical stenosis,25 and tubal dysfunctions from pelvic inflammatory disease 
(PID).25 Thus, because of these changes in the cervix from CIN and effects from cervical 
surgeries as treatment, CIN and cervical surgeries may affect fecundability. 
Loop Electrosurgical Excision Procedure (LEEP) 
LEEP is performed under local analgesia and uses a wire loop electrode 
that is on the end of an insulated handle. The electrode is used to cut and 
coagulate at the same time, and is sufficient enough to excise the unwanted tissue 
without causing thermal damage.18  The procedure’s success rate, defined as 
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removing the abnormal cells and no follow up treatment, is upwards of 98%.26  As 
a result of LEEP, cervical stenosis, secondary infection and changes in the 
cervical mucus all could have an impact on fertility. Two smaller studies 
examined LEEP and fertility found little association between surgical excision 
and fertility outcomes.25 27 The first was a retrospective cohort study,  which 
comprised 250 women from the original 1,000 participants who answered a 
questionnaire on fertility and menstrual symptoms 3 years after their LEEP 
procedure (Table 1). Because this study recruited women from another cohort, it 
was restricted to women who were followed up post LEEP. There was little 
difference between treated and untreated women in regards to fertility and 
menstrual symptoms.25 The second was a prospective cohort study that comprised 
574 women treated with LEEP, and found that LEEP did not have adverse effects 
on pregnancy outcomes (Table 1).27 This study was conducted at a single hospital 
in Montreal, and only followed up with women for 3 years. A more recent 
population-based case-control study of 303 cases and 1021 controls (Spracklen et 
al.) found that the LEEP procedure was associated with longer time-to-pregnancy 
(TTP) (OR=2.47, 95% CI; 1.10 –5.55).24 
Cryosurgery 
During cryosurgery, a circular metal probe is placed on the transformative 
zone of the cervix. Hypothermia is produced through the metal probe, and 
cryonecrosis is achieved by crystallizing intracellular water.18 Success rates range 
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from 77% to 93%.28 29 This procedure is used as a more conservative ablative 
method, and was found to be comparable to those of other ablative methods.30 
Once again, there have been inconsistent results regarding fertility and 
cryotherapy. Dolman et al. found that 96% and 95% of CIN1 and CIN2/3 patients 
respectively, were successfully treated and that fertility was not impaired.30 
However, Spracklen et al. found that women treated with cryosurgery had 
increased risk of longer TTP (OR=1.72, 95% CI: 0.69–4.25).24 
Conization 
Conization can be performed under general or local analgesia and can be 
performed with a knife cone or a laser. It typically uses a focused laser to make an 
ectocervical circumferential incision, usually around 1 cm. Small hooks are then 
used to manipulate the cone to get a deeper incision in the tissue.18 Studies of 
fertility and pregnancy following conization procedures have reported conflicting 
results. A small prospective cohort study of 460 women treated with conization 
from 1985 to 1999, found little evidence for adverse effects on fertility (Table 
1).31 Spracklen et al. found that women treated with cone biopsy had increased 
risk of longer TTP (OR=1.64, 95% CI: 0.70–3.86).24 A systematic review and 
meta-analysis on CIN treatment and birth outcomes found that more radical 
excisional techniques like cold knife and laser conization had a higher risk of 
preterm birth compared with ablative surgeries.21  
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Laser Ablation 
Laser ablation uses a laser beam to destroy the transformative zone tissue. 
The amount of destroyed tissue is determined by the duration of laser exposure.18 
Again, there have been studies analyzing laser procedures in relation to risk of 
fertility and adverse pregnancy outcomes, but findings have been inconsistent. 
One study found that risk of preterm birth was higher for excisional procedures 
compared with ablative surgeries, such as laser.21 However, similar to LEEP, 
Spracklen et al. found that the laser procedure was associated with longer TTP 
(OR=3.81, 95% CI: 1.17 –12.37). 24 
 
HPV and Fecundability 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the United States;32 39.9% of women in the United States had evidence of a 
current infection in 2014. 33  HPV is a common cause of cancers of the cervix,34 vagina, 
penis, rectum, and oral cavity.35 Among the many strains of HPV, HPV type 16 is the 
major strain that causes cervical cancer.36 One prospective cohort study of 241 women 
found that the cumulative incidence of CIN2/3 was 28% among women with a positive 
HPV test, and the highest risk was among women with HPV type 16 and 18.37 
The HPV vaccine became available in 2006. It protects against strains of HPV 
that may cause cervical cancer, CIN and genital warts.38 Since the implementation of the 
HPV vaccine and screening, both have been highly effective in preventing HPV infection 
and there has been a decline in the incidence of cervical cancer.17 One study in New 
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Mexico found that between 2007 to 2014, after the implementation of cervical screening 
and HPV vaccines, there was a decrease in the incidence rate of all grades of CIN for 
females ages 15-19 years old and CIN2 for women aged 20-24 years old.39 The HPV 
vaccines directly targeted HPV type 6,11, 16 and 18.39 There were similar results from 
Australia in 2011 that found after three years of establishing a HPV vaccination program, 
the incidence of high grade CIN was reduced.40 One study examined the association 
between HPV vaccination and fecundability. The HPV vaccine was found to have little 
effect on fecundability overall, but was positively associated with fecundability among 
women with a history of STIs.41 Because HPV is known to cause CIN and the HPV 
vaccine may affect fecundability, HPV and the HPV vaccine may be an important 
variable to adjust for in analyzing the association between CIN and fecundability.  
 
Previous studies of cervical dysplasia and fecundability 
Some studies have reported small associations between CIN treatment surgeries 
and fecundability. One study specifically examined the complications of the cone biopsy, 
and found cervical stenosis to be most common among women who had long cones 
removed.42 Two studies found little effect of LEEP on fertility or menstrual function.43 25 
However, these studies were very small, older, and retrospective in design, and were not 
consistent in their use of measures to quantify TTP. TTP is a measure that is more 
sensitive to small decreases in fertility than the typical binary measurement of infertility 
(i.e., >12 months or not). There have been few studies that have specifically examined 
HPV, CIN, treatments and TTP.  
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In a 2013 population-based case-control study, Spracklen et al. analyzed data 
from 1324 female participants from the Iowa Health in Pregnancy Study (IHIPS) aged ≥ 
18 years, with singleton live births during May 2002 to June 2005, and who did not have 
a history of -gestational type-I or type-II diabetes mellitus, systemic lupus, or chronic 
renal disease (Table 1).24 All potential cases and controls were identified from the Iowa 
electronic birth certificate file. Cases comprised 152 women with one prior cervical 
surgery and 151 women with colposcopy only. There were 1021 controls with no 
colposcopy or prior cervical surgery. Birth outcomes were validated with delivery records 
from each hospital, and CIN and cervical surgeries information was gathered by self-
report. Infertility was measured as ≥12 months of sexual intercourse without 
contraception trying to conceive, and was based on self-report. After controlling for 
household income, education, age, pre-pregnancy BMI, smoking and case status (PTD, 
SGA or control), Spracklen et al. found a two-fold increase in infertility among women 
with any type of cervical surgery (cone biopsy, LEEP, cryosurgery, or laser vaporization) 
(OR=2.09, 95% CI: 1.26–3.46) but little effect of colposcopy alone on infertility. 24 
Overall, longer TTP was most prevalent among women treated for cervical dysplasia 
compared with untreated women (16.4% and 8.4%, respectively). However, this study 
included only 152 women with a history of cervical surgery, and 151 women with a 
colposcopy only. This study was also retrospective in design and was restricted to 
already-pregnant women, and therefore would not capture women who never conceived. 
This study also defined infertility as a dichotomous variable and did not directly measure 
TTP. 
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Another study specifically examined pregnancy incidence and outcomes and 
found somewhat conflicting results (Table 1).44 This study was a retrospective cohort 
study that enrolled 6,179 women treated for CIN between 1974 and 2001, and 30,436 
controls. Participants were followed up for pregnancy outcomes until death, emigration, 
sterilization or until 2004. After controlling for number of pregnancies (0, 1, 2, and ≥3) 
and children (0, 1, 2, and ≥3) before CIN treatment, whether or not the type of pregnancy 
in question had already before the treatment, municipality and age, both the incidence of 
pregnancy (hazard ratio (HR)=1.20; 95% CI: 1.15–1.26) and livebirths (HR=1.12; 95% 
CI: 1.06–1.18) were greater among the treated women compared with untreated women.44 
Major study results are shown in Table 1. Because results across the various studies are 
inconsistent, the effects of CIN on fertility require further investigation. 
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Table 1: Literature review of relevant articles 
 
Author Year 
of Pub 
Study design Study size Data 
Collection 
Method 
Years of 
enrollment/ 
follow up 
Control 
variables 
Main findings 
Luesley et 
al 
1985 Retrospective 
cohort study 
915 women 
examined that 
had a cone 
biopsy 
Medical 
records 
From 1976 to 
1982 
None 121 (13%) had 
primary or 
secondary 
hemorrhage, 153 
(17%) cervical 
stenosis and 39 
(4%) subsequent 
infertility or an 
abnormal 
pregnancy. 
Keijser et al 1992 Prospective 
cohort study 
424 patients 
with CIN, but 
not invasive 
carcinoma 
that had the 
LEEP 
procedure 
Medical 
records 
Women were 
enrolled from 
January 1982 
to January 
1988, all 
patients with 
cytological 
diagnoses 
consistent with 
CIN  
 
None For women with 
CIN3, 
pretreatment 
diagnosis 
corresponded in 
73% of cases. In 
91% of all 
patients the 
LEEP was 
sufficient for 
complete 
treatment. 
Bigrigg et al 1994 Retrospective 
cohort study 
250 women 
from the 
Medical 
records 
Originally 
enrolled in 
None 134 women 
reported no 
 
 
 
 
 
1
2
 
original 1,000 
in LEEP study 
answered a 
questionnaire 
on fertility 
and menstrual 
symptoms 
and self-
report 
1990, but were 
followed up 
with cervical 
cytology for 
longer than 2 
years, the 
questionnaire 
answered 
questions for 3 
years after the 
LEEP 
difference in 
fertility and 
menstruation for 
women that had 
the LEEP 
procedure, and 
those that did 
not. 
Ferenczy et 
al 
1995 Prospective 
cohort study 
574 women 
who had 
LEEP for CIN  
Medical 
records 
and self-
report 
Enrolled 
women from 
January 1990 
to October 
1992, and 
followed every 
6 months for 3 
years 
smoking LEEP to a max 
depth of 1.5 cm 
and mean frontal 
diameter of 1.8 
cm did not have 
adverse effects 
on pregnancy 
outcome 
Turlington 
et al 
1996 Retrospective 
cohort study 
 
Women seen 
in the 
colposcopy 
clinic at New 
Hanover 
Regional 
Medical 
Center; 79 
women who 
had been 
treated with 
Medical 
records 
Women were 
enrolled 
January 1991 
through 
December 
1992 
None 11/ 12 women in 
treatment group 
that wanted to 
become pregnant 
did, 7/7 women 
in the treatment 
group that 
wanted to 
become pregnant 
did 
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3
 
LEEP, 79 
controls were 
women who 
had a 
colposcopy 
and cervical 
biopsy 
Mazouni et 
al 
2005 Prospective 
cohort study 
460 women 
treated for 
CIN with cold 
knife 
conization 
Medical 
records 
Enrolled 
women that 
were treated 
from January 
1985 to June 
1999 
None 26 CIN 
reoccurrences, 
no participants 
developed 
carcinoma, and 
had little adverse 
effect on fertility 
Kalliala et 
al 
2011 Retrospective 
cohort study 
6179 women 
treated for 
CIN between 
1974 and 
2001, 30,436 
controls at 
Helsinki 
University 
Hospital in 
Finland 
Medical 
records 
Identified 
women from 
1974 to 2001 
who had 
treatment for 
CIN, and were 
followed up 
for pregnancy 
outcomes until 
death, 
emigration, 
sterilization or 
until 2004 
number of 
any 
pregnancies 
(0, 1, 2, and 
≥3) and 
children (0, 
1, 2, and 
3+) before 
treatment 
for CIN 
incidence of 
pregnancy 
and livebirths 
were increased 
among the 
women that got 
treatment 
compared to the 
control group 
 
Spracklen et 
al. 
2013 Case control 
study 
Already 
pregnant 
Medical 
records 
Identified 
women who 
had live births 
Household 
income, 
education, 
Women with a 
history of 
cervical 
 
 
 
 
 
1
4
 
women in 
IHIPS; 152 
women with 
one prior 
cervical 
surgery, 151 
women with 
colposcopy 
only, 1021 
controls 
and self-
report 
from 2002 to 
2005 
age, pre-
pregnancy 
BMI, 
smoking 
and case 
status 
(PTD, SGA 
or control) 
treatment for 
CIN are at two-
fold risk of 
subfertility, 
measured as a 
time to 
pregnancy of 
more than 12 
months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
SPECIFIC AIMS 
This study examines the association of cervical dysplasia and its treatment with 
TTP among the Pregnancy Study Online (PRESTO).45 
 
The three main hypotheses are as follows: 
Hypothesis 1: Women with a history of cervical dysplasia (e.g. abnormal Pap tests) will 
have a longer TTP than women without a history of cervical dysplasia, indicating a role 
for HPV infection in subfertility. 
Hypothesis 2: Women with persistent or recurrent cervical dysplasia (e.q. >2 abnormal 
Pap tests) will have a longer TTP than women whose cervical dysplasia resolves (e.g. 1 
abnormal Pap test). 
Hypothesis 3: Women with a surgery for cervical dysplasia 
(LEEP/cone/laser/cryosurgery) will have a longer TTP than women with dysplasia who 
did not undergo surgery, indicating possible effects of both dysplasia and surgery. 
Hypothesis 4: With increasing time since most recent procedure or cervical dysplasia 
diagnosis, TTP will return to that of untreated/undiagnosed women. 
 
 
 
 
16 
METHODS 
Study population 
Pregnancy Study Online (PRESTO) is an ongoing web-based prospective cohort 
study of women who are planning their pregnancy in the U.S. and Canada.45 The study 
began enrollment in June 2013 and participants are recruited mainly through advertising 
on social media and pregnancy related websites. Women are eligible for this study if they 
are between the ages of 21 and 45, not using contraception or fertility treatments, in a 
stable relationship with a male partner, and not currently pregnant. The participants 
complete a baseline questionnaire and bimonthly follow-up questionnaires online for up 
to 12 months or until pregnancy, whichever occurs first. Over 80% of participants 
completed at least one follow up questionnaire.45 
  
Assessment of cervical dysplasia, surgical procedures, and covariates 
At baseline, participants reported detailed data on lifestyle and behavioral factors, 
socio-economic status, medication use, reproductive and medical history, including 
whether or not they had an abnormal Pap tests, how many and at what age. They also 
provided information on whether they had any of the cervical procedures, colposcopy, 
conization, laser ablation, a loop procedure or cryotherapy. 
Women who reported more than 12 abnormal Pap tests or <13 years old for their 
first abnormal Pap test or cervical procedure were set to missing and then multiply-
imputed. Additionally, there were 24 women who reported an abnormal Pap test, but 
were unsure of all procedures, as well as women who indicated they had an abnormal Pap 
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test, but were unsure about the specific procedures they had (e.g., writing “don’t know” 
to all procedures when asked). We set the procedures to missing and then imputed the 
data for these women.  Finally, because the colposcopy procedure will occur before any 
surgical procedure, women who indicated they had a surgical procedure but were not sure 
if they had a colposcopy or indicated that they did not have a colposcopy were assumed 
to have also had a colposcopy procedure. 
  
Assessment of time- to-pregnancy (TTP) 
At baseline, participants reported the date of last menstrual period (LMP), their 
typical menstrual cycle length, and the number of menstrual cycles they had been trying 
to conceive. On every follow up questionnaire, the participants reported their pregnancy 
status and LMP date. We calculated TTP, in cycles, as: cycles trying to conceive at the 
study entry + ((LMP date from most recent follow up questionnaire -  date of baseline 
questionnaire)/ cycle length) + 1. Participants contributed cycles from study entry until 
conception, fertility treatment, loss to follow up, or 12 cycles, whichever occurred first. 
  
Assessment of time since diagnosis or procedure 
At baseline, participants reported their date of birth and their ages at which they 
had an abnormal Pap test and/or any procedures to treat cervical dysplasia. To calculate 
the time since cervical dysplasia diagnosis or procedure, we subtracted the age at their 
most recent diagnosis or procedure from their age at the start of their current pregnancy 
attempt. 
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Cervical dysplasia validation 
To validate the self-reported data on cervical dysplasia, abnormal Pap tests, and 
cervical surgeries, we mailed letters and medical record release forms to 150 women 
enrolled between January 1, 2018 and March 20, 2018 who reported an abnormal Pap 
test. In the letter, we explained our objective of examining the association between 
abnormal Pap tests and fertility, and we requested permission to obtain medical records 
from their provider to verify their information on cervical dysplasia, abnormal Pap tests, 
and cervical surgeries. Women were asked to sign and return a medical records release 
form in a business return envelope. To date, 8 medical record release forms have been 
returned; 5 medical records have been received and all 5 diagnoses of cervical dysplasia 
(100%) were confirmed by the study gynecologist (Dr. Rebecca Perkins). The PRESTO 
study is examining how to improve overall participation in the validation study, such as 
by sending follow-up letters or by phone calling participants. 
  
Exclusions 
As of March 22, 2018, a total of 7,132 eligible women had enrolled and 
completed a baseline questionnaire. We excluded 98 women because they had a baseline 
LMP > 6 months prior to baseline, 11 women with LMP date greater than the date the 
questionnaire was completed, and 27 women with no prospective LMP dates of 
pregnancy over follow up. Finally, in an effort to reduce potential for selection bias, 
1,402 women were excluded because they had pregnancy attempt times greater than 6 
cycles at study entry. A total of 5,594 women comprised the analytic sample. 
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Data analysis 
We evaluated the association between cervical dysplasia (abnormal Pap test or 
never had abnormal Pap test), age at first abnormal Pap test (in years), colposcopy (yes 
vs. no), conization (yes vs. no), laser ablation (yes vs. no), loop procedure (yes vs. no), 
and cryotherapy (yes vs. no) and fecundability for the women in the study. We calculated 
unadjusted fecundability, which is the total number of pregnancies/total number of 
cycles. We then used proportional probabilities regression models to estimate 
fecundability ratios (FR) and 95% confidence intervals (CI).  
 
Models 
We evaluated the association between cervical dysplasia (abnormal Pap test or 
never had abnormal Pap test), age at first abnormal Pap test (in years), colposcopy 
(yes vs. no), conization (yes vs. no), laser ablation (yes vs. no), loop procedure (yes 
vs. no), and cryotherapy (yes vs. no) and fecundability for the women in the study. 
We calculated fecundability, defined as the total number of pregnancies/total number 
of cycles. We then used proportional probabilities regression models to estimate 
fecundability ratios (FR) and 95% confidence intervals (CI). We created four models 
for this study:  
1. The first model compared women who had abnormal Pap tests with women who 
had no abnormal Pap tests.  
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2. The second model compared women who had one abnormal Pap test with those 
that had two or more abnormal Pap tests. 
3. The third model examined each cervical procedure as compared with no abnormal 
Pap test. Because three of the procedures (conization, laser, and loop) were 
excisional procedures, we grouped them into one new variable. We also created a 
variable for women who had any cervical surgery (conization, cryosurgery, laser 
or loop).  
4. The fourth model examined time since procedure and diagnosis from their current 
pregnancy attempt, as compared with women who never had an abnormal Pap. 
We divided the time since variable into quartiles based on the distribution of each 
procedure. 
 
The FR in our study represents the average per-cycle probability of conception 
comparing the exposed with unexposed categories of women in each model. Selection of 
potential confounders was guided by literature, the drawing of causal diagrams, and 
associations seen in the data (e.g., Table 2.) We controlled for age (<25, 25-29, 30-34, 
>35 years), non-Hispanic white (yes vs. no), married to partner (yes vs. no), household 
income (<49 000, 50 000-99 000, 100 000-149 000, >150 000 USD), education (less than 
12th grade, high school degree/GED, some college/vocational school, college degree (4 
years), graduate degree), region of residence (U.S. Midwest, Northeast, South, West; 
Canada), BMI (kg/m2), smoking (current, past, never), hormonal last method of 
contraception (yes vs. no), male partner circumcised (yes vs. no), number of sexual 
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partners, history of sexually transmitted infections and/ or pelvic inflammatory disease 
(yes vs. no), and HPV vaccine (yes vs. no).  
We used a Markov chain Monte Carlo method to multiply impute missing 
outcome, exposure, and covariate data.  We generated five imputation data sets using 
PROC MI and combined point estimates and standard errors from each data set using 
PROC MIANALYZE.  For women who did not completed any follow-up questionnaires, 
we assigned them one cycle of follow-up and imputed their pregnancy status.  Finally, we 
used the weighted copy method to improve convergence of the regression model.46 All 
statistical analyses were performed using SAS version 9.4.47
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RESULTS 
 
Table 2 shows baseline characteristics of the 5,594 women in this analysis. 
Women who had abnormal Pap tests and no abnormal Pap tests had roughly similar ages, 
30.0 years old and 29.9 years old respectively. Women who had abnormal Pap tests were 
slightly less likely to be married (90.6%) than women with no abnormal Pap test (92.2%). 
Women with abnormal Pap tests were more likely to be non-Hispanic white (85.3%) than 
women with no history of abnormal Pap test (82.5%). A history of abnormal Pap test was 
positively associated with current and past smoking, gravidity, parity, irregular menses, 
number of sexual partners, history of chlamydia, genital warts and herpes, as well as a 
history of pelvic inflammatory disease. A history of abnormal Pap test was inversely 
associated with income, BMI, education, doing something to improve the chances of 
conceiving, history of miscarriage, and history of infertility. Women with a history of 
abnormal Pap tests were also more likely to have had the HPV vaccine (38.8%) 
compared to women with no history of abnormal Pap (34.2%), and have an older age at 
first HPV vaccine (21.4 years) compared with women with no history of abnormal Pap 
test (20.9 years). Of the women with an abnormal Pap test, the average age at first 
abnormal Pap test was 23.0 (std=4.5) and the average number of abnormal Pap tests was 
2.1 (std=1.7). 
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Table 2. Baseline characteristics of women by abnormal Pap test 
 
Characteristica Abnormal 
Pap Test 
No Abnormal 
Pap Test 
Number of Participants (%) 2,047 (36.6) 3,547 (63.4) 
Age (years, mean) 30.0 29.9 
Partners Age (years, mean) 32.2 31.8 
Married to partner (%) 90.6 92.2 
Non-Hispanic white (%) 85.3 82.5 
Household income <$50,000 USD (%) 18.4 21.4 
Less than a college degree (%) 28.5 25.3 
Geographic region (%) 
        Midwest 
        Northeast 
        South 
        West 
        Canada 
 
20.2 
26.2 
25.8 
13.8 
14.6 
 
17.8 
25.3 
23.8 
16.2 
16.9 
Physical activity (MET-h/week, mean)b 35.2 34.8 
Body mass index (BMI, kg/m2)c 
        <25 (%) 
        25-29 (%) 
        >30 (%) 
 
47.8 
25.3 
26.9 
 
45.9 
23.4 
30.7 
Use of multivitamins or folate (%) 79.5 79.5 
Current/occasional smoker (%) 
Past smoker (%) 
Never smoker (%) 
13.3 
17.7 
69.1 
9.6 
13.8 
76.6 
Alcohol intake (drinks/week, mean) 3.8 3.0 
Perceived stress scale score (mean) 16.1 16.0 
Ever been pregnant (%) 51.3 47.7 
Parous (%) 30.4 29.6 
Irregular menses (%) 17.5 16.9 
Doing something to improve chances of 
conception (%) 
75.2 75.5 
Intercourse frequency <1 time/week (%) 19.1 21.6 
Intercourse frequency >4 times/week (%) 17.0 16.5 
 
 
 
24 
Hormonal last method of contraception 
(%) 
42.3 37.7 
History of miscarriage (%) 39.7 41.6 
History of infertility (%) 12.6 13.7 
Male partner circumcised (%) 76.3 75.1 
Number of sexual partners (mean) 9.5 6.9 
History of sexually transmitted infection 
(STI) 
        Chlamydia (%) 
        Genital warts (%) 
        Herpes (%) 
 
11.5 
6.1 
5.5 
 
5.4 
1.6 
3.1 
Pelvic inflammatory disease (%) 1.8 0.7 
Human Papilloma Virus (HPV) vaccine 
(%) 
38.8 34.2 
Age at first HPV vaccine (years, mean)d 21.4 20.9 
Age at first abnormal Pap test (years, 
mean) 
23.0 -- 
Number of abnormal Pap tests (mean) 2.1 -- 
 
a All characteristics are standardized to age distribution of cohort at baseline 
b MET= metabolic equivalent of task 
c BMI= body mass index 
d Restricted to women with the HPV vaccine 
 
 
 
25 
 
Table 3 shows the distribution of surgical procedures, colposcopy, conization, 
cryosurgery, laser ablation and LEEP procedure of the 2,047 women who reported having 
had an abnormal Pap test. Most of the women had a colposcopy procedure (78.8%), 
which is expected because physicians typically perform a colposcopy before doing a 
more invasive procedure. Conization (38.9%) and the LEEP (20.0%) were the two most 
common surgical procedures. 
 
 
 
Table 3. Cervical procedures for women who had abnormal Pap test 
 
Procedureab Abnormal Pap Test 
n=2,047 
Colposcopy (%) 1,613 (78.8) 
Conization (%) 796 (38.9) 
Cryosurgery (%) 252 (12.3) 
Laser ablation (%) 70 (3.4) 
LEEPc (%) 409 (20.0) 
a procedures were of the women (n=2,047) who had an abnormal Pap test 
b Participants may contribute to more than one “procedure” category 
c LEEP= electrosurgical excision procedure 
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We analyzed the distribution of the continuous variables in our dataset; number of 
abnormal Pap tests, age at first abnormal Pap test, age at first colposcopy, age at first 
conization, age at first LEEP procedure, age at first cryosurgery, and age at first laser 
ablation. These distributions were analyzed to check for outliers in the data. Prior to 
multiple imputation, we set cut offs for maximum number of abnormal Pap tests and 
minimum ages for first abnormal Pap test and each of the procedures. The average 
number of abnormal Pap tests was 2.1 (std=1.7) abnormal Pap tests, with a range of 1-12 
abnormal Pap tests (Figure 1). The average age at first abnormal Pap test was 23.5 
(std=4.6), with a range of 13-39 years (IQR=6.0) (Figure 2). 
The ages at first procedure were also analyzed. The average age at first 
colposcopy was 24.00 (std=4.5), with a range of 13-40 years (IQR=6.0) (Figure 3). The 
average age at first conization was 24.1 years old (std=4.5), with a range of 13-40 years 
(IQR=6.0) (Figure 4). The average age at first LEEP was 25.2 years old (std=4.4), with a 
range of 13-39 years (IQR=6.0) (Figure 5). The average age at first laser ablation was 
25.4 (std=2.8), with a range of 13-39 years (IQR=3.0) (Figure 6). The average age at first 
cryosurgery was 23.6 years (std=4.3), with a range of 13-38 years (IQR=5.0) (Figure 7). 
 
 
 
 
 
 
 
 
 
27 
 
 
Figure 1: Distribution of number of abnormal Pap tests 
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Figure 2: Age at first abnormal Pap test 
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Figure 3: Age at colposcopy 
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Figure 4: Age at conization  
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Figure 5: Age at LEEP 
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Figure 6: Age at laser ablation 
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Figure 7: Age at cryotherapy 
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Overall there was little association between history of abnormal Pap test 
(FR=1.03, 95% CI: 0.96, 1.11) and fecundability. The results did not differ when the data 
were examined by number of abnormal Pap tests (1 vs. none: FR 1.02, 95% CI: 0.92, 
1.13; 2 or more vs. none: FR 1.04, 95% CI: 0.96, 1.14). 
Results were consistent across subgroups of procedures (Table 4). We analyzed 
women who had a colposcopy, any excisional surgery (conization, LEEP, and laser), and 
cryosurgery. Compared with no abnormal Pap test, FRs were 1.03 (95% CI: 0.96, 1.12) 
for colposcopy, 1.04 (95% CI 0.95, 1.15) for any excisional surgery, 0.96 (95% CI: 0.76, 
1.22) for cryosurgery, and 1.04 (95% CI: 0.95, 1.13) for any surgery (conization, LEEP, 
laser, or cryosurgery). 
In a model that mutually adjusted for each procedure, the results were similar but 
less precise. Compared with no abnormal Pap test, FRs were 1.03 (95% CI: 0.93, 1.15) 
for colposcopy, 1.00 (95% CI 0.88, 1.13) for any excisional surgery, 0.97 (95% CI: 0.81, 
1.16) for cryosurgery, and 1.05 (95% 0.71, 1.55) for any surgery (conization, LEEP, 
laser, or cryosurgery). 
 
 
 
 
 
Table 4: Fecundability ratios for abnormal Pap tests and for cervical procedures 
 
 
 
 
 
FR=fecundability ratio, Cl= confidence interval. Reference group for all comparison is “no history of abnormal Pap 
test”. Participants may contribute to more than one “procedure” category. 
a includes cone, loop and laser 
b includes cone, loop, laser and cryotherapy 
c adjusted for age, marriage status, race, income, education geographical region, BMI, smoking status, history of STI 
and PID, hormonal birth control, number of sexual partners and history of HPV vaccine 
d additionally adjusted for each procedure in the model as well, colposcopy, any excisional surgery, and cryotherapy 
 
Exposure 
 
No. of 
Cycles 
 
No. of 
Pregnancies 
 
Unadjusted FR 
(95% CI) 
 
Adjusted FR 
(95% CI)c 
 
Adjusted FR 
(95% CI)d 
Abnormal Pap test 
    None 
    Any 
        1 abnormal Pap test 
        >2 abnormal Pap test 
 
 
8,078 
4112 
3966 
 
 
1,190 
609 
581 
 
1.00 (reference) 
1.01 (0.95, 1.08) 
1.01 (0.93, 1.10) 
1.01 (0.93, 1.10) 
 
1.00 (reference) 
1.03 (0.96, 1.11) 
1.02 (0.92, 1.13) 
1.04 (0.96, 1.14) 
 
 
Procedures 
     Colposcopy 
     Any excisional surgerya 
     Cryotherapy 
     Any surgeryb 
 
6402 
4076 
1028 
4424 
 
943 
583 
135 
632 
 
1.01 (0.94, 1.09) 
1.00 (0.92, 1.09) 
0.95 (0.81, 1.12) 
1.00 (0.92, 1.08) 
 
1.03 (0.96, 1.12) 
1.04 (0.95, 1.15) 
0.96 (0.76, 1.22) 
1.04 (0.95, 1.13) 
 
1.03 (0.93, 1.15) 
1.00 (0.88, 1.13) 
0.97 (0.81, 1.16) 
1.05 (0.71, 1.155 
3
5
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The mean time since diagnosis or cervical procedure was 6.07 years (std=4.5), 
with an interquartile range of 7 years (Figure 8). Overall there was little association 
between time since diagnosis/procedure and fecundability (Table 5), albeit there was a 
slight decrease in fecundability within the first 2 years of diagnosis/ procedure: FR=0.96, 
95% CI: 0.84, 1.10, with FRs that tended to increase with increasing time since 
diagnosis/procedure. A cubic spline of this data with 4 knots at 1, 4, 7 and 10 years 
demonstrates a positive trend between time since diagnosis and fecundability (Figure 13). 
The mean time since cervical dysplasia diagnosis to pregnancy attempt was 6.2 
years (std=4.59), with an interquartile range of 7 years (Figure 9). There was little 
association between time since diagnosis and fecundability (Table 5). The mean time 
since colposcopy procedure to pregnancy attempt was 5.7 years (std=4.1), with an 
interquartile range of 7 years (Figure 10). There was once again little association between 
time since colposcopy procedure and fecundability (Table 5). The mean time since any 
excisional procedure to pregnancy attempt was 5.7 years (std=4.36), with an interquartile 
range of 7 years.  There was little association between time since excisional procedure 
and pregnancy attempt and fecundability (Table 5), but a slight decrease in fecundability 
within the first 2 years of excisional procedure: FR=0.96, 95% CI: 0.81,1.13, with FRs 
that tended to increase with increasing time since excisional procedure. The mean time 
since cryosurgery to pregnancy attempt was 8.6 years (std=4.78), with an interquartile 
range of 6 years (Figure 12). There was little association between time since cryosurgery 
and pregnancy attempt (Table 5). 
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Figure 8. Time since diagnosis or procedure and current pregnancy attempt  
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Figure 9. Time since diagnosis only and current pregnancy attempt  
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Figure 10. Time since colposcopy procedure only and pregnancy attempt 
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Figure 11. Time since excisional procedure only and pregnancy attempt 
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Figure 12. Time since cryosurgery only and pregnancy attempt  
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Table 5. Fecundability ratios by time since last procedure/diagnosis 
 
FR=fecundability ratio, Cl= confidence interval. Reference group for all comparison is 
“no history of abnormal Pap test”. 
a includes most recent cervical dysplasia diagnosis or any procedure 
b includes only women that have had an abnormal Pap test and no procedure 
c includes women who have been diagnosed and have only had a colposcopy procedure 
Exposure No. of 
Cycles 
No. of 
Pregnancies 
Unadjusted FR 
(95% CI) 
Adjusted FR 
(95% CI)f 
Time Since: 
    No abnormal Pap 
    Diagnosis/Any procedurea 
        Q1: < 2 years 
        Q2: 2-6 years 
        Q3: 6-8 years 
        Q4: ≥ 9 years 
 
14,179 
 
2174 
2539 
1578 
1787 
 
2048 
 
289 
408 
237 
256 
 
1.00 (reference) 
 
0.94 (0.83, 1.07) 
1.06 (0.96, 1.18) 
1.05 (0.90, 1.22) 
0.99 (0.88, 1.12) 
 
1.00 (reference) 
 
0.96 (0.84, 1.10) 
1.05 (0.95, 1.17) 
1.06 (0.91, 1.22) 
1.08 (0.94, 1.23) 
    Diagnosis onlyb 
        Q1: < 2 years 
        Q2: 2-5.5 years 
        Q3: 5.5-8 years 
        Q4: ≥ 9 years 
 
443 
398 
436 
399 
 
62 
64 
67 
54 
 
0.94 (0.72, 1.23) 
1.15 (0.92, 1.44) 
0.96 (0.76, 1.22) 
0.99 (0.75, 1.31) 
 
0.97 (0.76, 1.25) 
1.16 (0.93, 1.45) 
0.95 (0.75, 1.19) 
1.04 (0.79, 1.37) 
    Colposcopy onlyc 
        Q1: < 2 years 
        Q2: 2-5 years 
        Q3: 5-8 years 
        Q4: ≥ 9 years 
 
542 
539 
548 
349 
 
83 
84 
85 
59 
 
1.00 (0.82, 1.24) 
1.06 (0.87, 1.29) 
1.07 (0.86, 1.32) 
1.04 (0.83, 1.30) 
 
1.01 (0.82, 1.25) 
1.01 (0.83, 1.23) 
1.04 (0.85, 1.28) 
1.13 (0.90, 2.43) 
    Excision procedured 
        Q1: < 2 years 
        Q2: 2-5 years 
        Q3: 5-8 years 
        Q4: ≥ 9 years 
 
979 
819 
938 
660 
 
128 
131 
140 
98 
 
0.94 (0.79, 1.10) 
1.09 (0.92, 1.28) 
1.01 (0.85, 1.20) 
1.03 (0.83, 1.27) 
 
0.96 (0.81, 1.13) 
1.07 (0.90, 1.27) 
1.05 (0.89, 1.24) 
1.12 (0.91, 1.37) 
    Cryosurgerye 
        Q1: < 6 years 
        Q2: 6-8 years 
        Q3: 8-11 years 
        Q4: ≥ 12 years 
 
366 
188 
281 
193 
 
45 
33 
29 
28 
 
0.93 (0.67, 1.28) 
1.17 (0.86, 1.61) 
0.80 (0.55, 1.16) 
0.96 (0.68, 1.17) 
 
0.97 (0.69, 1.34) 
1.23 (0.89, 1.71) 
0.81 (0.56, 1.16) 
1.20 (0.82, 1.74) 
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d includes women who have been diagnosed and have had an excisional procedure 
(conization, laser and LEEP) 
e includes women who have been diagnosed and have had a cryosurgery procedure 
f adjusted for age, marriage status, race, income, education geographical region, BMI, 
smoking status, history of STI and PID, hormonal birth control, number of sexual 
partners and history of HPV vaccine 
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Figure 13. Restricted cubic spline of time since diagnosis/procedure and 
fecundability with 4 knots at 1, 4, 7 and 10 years.
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DISCUSSION 
 
 We found little association overall between a history of abnormal Pap test –  a 
proxy for cervical dysplasia – and fecundability. We also found little association between 
women with treatments for cervical dysplasia, including excisional surgeries. Recency of 
diagnosis or procedure did not appreciably affect these findings. Although we found a 
very slight decrease in fecundability within the first two years since diagnosis or 
procedure, fecundability became similar to that of undiagnosed/untreated women after 2 
years, and then increased slightly.  
Although one previous study that analyzed CIN treatment and fertility reported a 
two-fold increase risk of prolonged TTP for women with CIN treatments compared with 
untreated women, 24 this study was retrospective in design, had a small sample size and 
relied on self-reported data for exposure and outcome. In addition, this study was limited 
to women who were already pregnant, thus excluding women who could not conceive. 
Our results are consistent with other studies demonstrating no clear adverse effects on 
fertility of CIN treatments.44 27 25 43 
 One study limitation includes our reliance on self-reported data on abnormal Pap 
tests, procedures, and ages. We attempted to validate self-reported data using medical 
records for recently-enrolled participants, but we received very few medical records back. 
Another limitation is that our study is internet-based, and the recruitment of participants 
may be prone to selection bias. There could be differences between women who use the 
internet and those that do not, but the recruitment should not affect the validity unless the 
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relation between the study factors differ between internet users and non-users, which is 
unlikely. We see no reason that the relation between cervical dysplasia and fecundability 
would be different among internet users and non-users. Furthermore, as our study48 and 
others have shown,49 50 even when participation in a cohort study is associated with 
characteristics like age, parity and smoking, biased due to self-selection is not necessarily 
present. 
In our study, because age is related to potential abnormal Pap tests, procedures, 
and fecundability, and the accuracy of recall likely decreases with increasing age, 
differential exposure misclassification may have biased the FR results. As shown in the 
time since each diagnosis or procedure distributions (Figure 8-12), some women had as 
many as 23 years since their diagnosis or procedure and their most recent pregnancy 
attempt. Our study was also limited to women planning a pregnancy. If unplanned 
pregnancies are more common among women who are more fertile or never had an 
abnormal Pap test, exclusion of unplanned pregnancies could have introduced selection 
bias. 
This is the largest study on cervical dysplasia, surgical treatments for dysplasia, 
and fecundability, as well as the only study to analyze the effect of time since diagnosis 
or procedure. Other strengths of this study include the prospective design and 
geographically dispersed population, including participants residing in all US states and 
Canadian provinces. Data were collected on a wide range of potential confounders, 
including exercise, dietary factors, socioeconomic factors (e.g., education, income), as 
well as data on their partner.  
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CONCLUSION 
  We found little association overall between a history of abnormal Pap test –  a 
proxy for cervical dysplasia – and fecundability, as well as little association between 
cervical procedures and fecundability. There was also little association between time 
since the diagnosis or procedure and pregnancy attempt and fecundability. Because CIN 
and surgical treatments affect cervical tissue and functions of the cervix, the association 
to fertility needs further examination. Future research, might include use of registry-
based data or medical records to document the specific diagnosis and treatments. This 
would improve the accuracy of outcome classification and reduce potential for detection 
bias. 
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